|
28 Oct 2019 |
First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda's Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints
|
|
28 Oct 2019 |
Microbion Corporation Announces Results from Randomized, Double Blind, Placebo-Controlled Phase 1b Trial of Pravibismane (MBN-101) for Treatment of Moderate to Severe Chronic Infected Diabetic Foot Ulcers
|
|
28 Oct 2019 |
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual Conference
|
|
28 Oct 2019 |
Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|
|
28 Oct 2019 |
Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome
|
|
26 Oct 2019 |
LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study
|
|
25 Oct 2019 |
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
|
|
25 Oct 2019 |
European Commission Approves Astellas' XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
|
|
25 Oct 2019 |
Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients
|
|
25 Oct 2019 |
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
|
|
24 Oct 2019 |
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
|
|
23 Oct 2019 |
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC Targeted Protein Degraders
|
|
23 Oct 2019 |
RAPT Therapeutics Announces Initiation of First-in-Human Phase 1 Study of RPT193
|
|
23 Oct 2019 |
Oligomerix Presents Preclinical Data on Lead Alzheimer’s Disease Candidate at Neuroscience 2019
|
|
23 Oct 2019 |
Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
|
|
22 Oct 2019 |
Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease
|
|
22 Oct 2019 |
Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer
|
|
22 Oct 2019 |
Cerevel Therapeutics Initiates Phase 1b Clinical Trial of CVL-231, a M4 Selective Positive Allosteric Modulator in Development for the Treatment of Schizophrenia
|
|
22 Oct 2019 |
ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference
|
|
22 Oct 2019 |
FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
|
|
21 Oct 2019 |
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
|
|
21 Oct 2019 |
Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
|
|
21 Oct 2019 |
Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
|
|
21 Oct 2019 |
Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes
|
|
21 Oct 2019 |
Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/ Refractory FLT3-ITD AML
|
